A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib

NCT04494659 | Completed Phase 1

• 1 other identifier: FMTN-I-105
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of the study was to assess the effect of repeated oral doses of Rifampicin on the pharmacokinetic profile of a single dose of Famitinib. The secondary objective of the study was to assess the safety of Famitinib given alone versus Famitinib co-administered with Rifampicin.

Conditions

Healthy Adult Subjects

Outcome Measures

Primary Outcomes (3)

• Cmax of Famitinib

  Pharmacokinetics parameters of Famitinib

  Day 1 to Day 24

• AUC0-t of Famitinib

  Pharmacokinetics parameters of Famitinib

  Day 1 to Day 24

• AUCinf of Famitinib

  Pharmacokinetics parameters of Famitinib

  Day 1 to Day 24

Secondary Outcomes (5)

• Tmax of Famitinib

  Day 1 to Day 24

• T1/2 of Famitinib

  Day 1 to Day 24

• CL/F of Famitinib

  Day 1 to Day 24

• Vz/F of Famitinib

  Day 1 to Day 24

• incidence of adverse events/serious adverse events

  from ICF signing date to approximate Day 31

Study Arms (1)

Single arm

EXPERIMENTAL

single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16

Drug: Famitinib capsule; Drug: Rifampicin capsule

Interventions

Famitinib capsule DRUG

single dose and co-administrated with Rifampicin capsule

Also known as: SHR1020

Single arm

Rifampicin capsule DRUG

repeated doses of Rifampicin capsule

Also known as: Rifampicin

Single arm

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subjects aged 18 to 50 years old at the date of signing the informed consent;
• Male body weight ≥ 50kg, body mass index (BMI) within the range of 19 \~ 28 kg/m2 (including 19 and 28) (BMI= weight (kg)/height 2 (m2));
• Subjects have no childbirth plans and agree to take effective contraceptive measures within 3 months of the last medication;
• The subject can communicate well with the researcher, understand and comply with the requirements of the study, understand and sign the informed consent.

You may not qualify if:

• History of or currently suffering from any serious clinical diseases such as diseases in circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry, and metabolic abnormalities, or any other diseases may interfere with the test results;
• Any surgery within 6 months before screening, or plan to perform surgery during the study period, or who have previously undergone any surgery that affects gastrointestinal absorption (including gastrectomy, bowel resection, gastric reduction surgery, etc.)
• Blood donation or massive blood loss (≥200 mL), or received blood transfusion, or used blood products within 3 months before screening;
• History of allergy to drugs, food or other substances;
• Frequent use of sedatives, sleeping pills or other addictive drugs; History of drug abuse within 1 year prior to screening; Positive for urine drug abuse screening test;
• Participated in any clinical trial and took the study drug within 3 months prior to the first administration;
• Used any prescription drug or herbal tonic within 1 month before the first administration; Have used any over-the-counter (OTC) medicines, food supplements (including vitamins, calcium tablets, etc.) within 2 weeks prior to the first administration;
• Those who had smoked more than 5 cigarettes per day in the previous 3 months before screening and could not stop using any tobacco products during the study period; Nicotinic test positive;
• Frequent drinkers in the previous 6 months before screening, i.e., those who drink more than 14 units of alcohol per week (1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine) and cannot stop using any alcoholic products during the study period; alcohol test positive;
• Abnormal vital signs, physical examination, 12-lead ECG, abdominal B-ultrasound, chest radiograph, routine blood test, biochemical test, routine urine test and blood coagulation test with clinical significance;
• Hepatitis B surface antigen positive, hepatitis C antibody positive, syphilis antibody positive, HIV antibody positive;
• Subjects have taken and do not agree to stop using any drink or food containing methylxanthine, such as coffee, tea, cola, chocolate, etc. from 48 hours before the first administration until end of the study;, subjects have taken and do not agree to discontinue any beverage or food containing grapefruit from 7 days prior to initial administration until end of the study; Those who have special requirements on diet and cannot follow a uniform diet;
• Subjects who are considered to have other factors that are not appropriate to participate in this study by the investigator.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266055, China

Location

Related Publications (1)

• Li T, Li X, Jiang X, Wang C, Sun F, Liu Y, Lin P, Shi P, Fu Y, Gao X, Zhang Y, Cao Y. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects. Cancer Chemother Pharmacol. 2022 Nov;90(5):409-415. doi: 10.1007/s00280-022-04474-8. Epub 2022 Sep 15.

  PMID: 36107220 DERIVED

MeSH Terms

Interventions

famitinib; Rifampin

Intervention Hierarchy (Ancestors)

Rifamycins; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Repeated oral doses of Rifampicin on the pharmacokinetic profile of a single dose of Famitinib.

Study Record Dates

• First Submitted: July 28, 2020
• First Posted: July 31, 2020
• Study Start: July 20, 2020
• Primary Completion: August 13, 2020
• Study Completion: August 31, 2020
• Last Updated: September 29, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)